Janus Henderson Group PLC Grows Position in 4D Molecular Therapeutics, Inc. $FDMT

Janus Henderson Group PLC lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 13.2% during the 1st quarter, Holdings Channel reports. The firm owned 5,247,151 shares of the company’s stock after acquiring an additional 611,276 shares during the period. Janus Henderson Group PLC owned about 0.10% of 4D Molecular Therapeutics worth $48,868,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics during the first quarter valued at about $46,000. Millennium Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after purchasing an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics in the first quarter worth about $39,000. American Century Companies Inc. grew its stake in shares of 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after purchasing an additional 5,026 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after purchasing an additional 2,284 shares during the period. Institutional investors own 99.27% of the company’s stock.

Insider Buying and Selling

In related news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Kirn sold 114,746 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 184,811 shares of company stock valued at $2,075,906. 7.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on FDMT shares. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research note on Friday, May 8th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.67.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $10.18 on Friday. 4D Molecular Therapeutics, Inc. has a one year low of $4.30 and a one year high of $14.00. The company has a 50-day simple moving average of $10.58 and a two-hundred day simple moving average of $9.65. The firm has a market capitalization of $532.21 million, a PE ratio of -3.96 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. Analysts expect that 4D Molecular Therapeutics, Inc. will post -3.81 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.